477 related articles for article (PubMed ID: 35057002)
1. Development of Pharmaceutical Nanomedicines: From the Bench to the Market.
Halwani AA
Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057002
[TBL] [Abstract][Full Text] [Related]
2. Current status and vision of local pharmaceutical industries in Saudi Arabia: The focus on nanomedicines.
Halwani AA; Balkhi B; Alamoudi AA; Almozain NH; Alajmi AM; Noorwali A; Badr MY; Noor AO; Bagalagel A; Tawfik EA
Saudi Pharm J; 2023 Aug; 31(8):101674. PubMed ID: 37448843
[TBL] [Abstract][Full Text] [Related]
3. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
Hock SC; Ying YM; Wah CL
PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
[TBL] [Abstract][Full Text] [Related]
4. Nanomedicines accessible in the market for clinical interventions.
Gadekar V; Borade Y; Kannaujia S; Rajpoot K; Anup N; Tambe V; Kalia K; Tekade RK
J Control Release; 2021 Feb; 330():372-397. PubMed ID: 33370576
[TBL] [Abstract][Full Text] [Related]
5. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.
Farjadian F; Ghasemi A; Gohari O; Roointan A; Karimi M; Hamblin MR
Nanomedicine (Lond); 2019 Jan; 14(1):93-126. PubMed ID: 30451076
[TBL] [Abstract][Full Text] [Related]
6. Development of Nanomedicines and Nano-Similars: Recent Advances in Regulatory Landscape.
Paliwal R; Kumar P; Chaurasiya A; Kenwat R; Katke S; Paliwal SR
Curr Pharm Des; 2022; 28(2):165-177. PubMed ID: 34781869
[TBL] [Abstract][Full Text] [Related]
7. Artificial intelligence aids in development of nanomedicines for cancer management.
Tan P; Chen X; Zhang H; Wei Q; Luo K
Semin Cancer Biol; 2023 Feb; 89():61-75. PubMed ID: 36682438
[TBL] [Abstract][Full Text] [Related]
8. Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics.
Choi YH; Han HK
J Pharm Investig; 2018; 48(1):43-60. PubMed ID: 30546919
[TBL] [Abstract][Full Text] [Related]
9. Advances and challenges in nanocarriers and nanomedicines for veterinary application.
Carvalho SG; Araujo VHS; Dos Santos AM; Duarte JL; Silvestre ALP; Fonseca-Santos B; Villanova JCO; Gremião MPD; Chorilli M
Int J Pharm; 2020 Apr; 580():119214. PubMed ID: 32165220
[TBL] [Abstract][Full Text] [Related]
10. European Commission-supported development of targeted nanomedicines: did MediTrans make a difference?
Storm G; Aime S
Ther Deliv; 2011 Jul; 2(7):861-4. PubMed ID: 22833900
[TBL] [Abstract][Full Text] [Related]
11. Trends in Nanomedicines for Cancer Treatment.
do Nascimento T; Todeschini AR; Santos-Oliveira R; de Souza de Bustamante Monteiro MS; de Souza VT; Ricci-Júnior E
Curr Pharm Des; 2020; 26(29):3579-3600. PubMed ID: 32186271
[TBL] [Abstract][Full Text] [Related]
12. Nanomedicine: a pharma perspective.
Brown PD; Patel PR
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(2):125-30. PubMed ID: 25196070
[TBL] [Abstract][Full Text] [Related]
13. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.
Kompella UB; Amrite AC; Pacha Ravi R; Durazo SA
Prog Retin Eye Res; 2013 Sep; 36():172-98. PubMed ID: 23603534
[TBL] [Abstract][Full Text] [Related]
14. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
Patel P; Shah J
Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
[TBL] [Abstract][Full Text] [Related]
15. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
[TBL] [Abstract][Full Text] [Related]
16. Issues affecting nanomedicines on the way from the bench to the market.
Longo JPF; Mussi S; Azevedo RB; Muehlmann LA
J Mater Chem B; 2020 Dec; 8(47):10681-10685. PubMed ID: 33155000
[TBL] [Abstract][Full Text] [Related]
17. Progress and challenges in the translation of cancer nanomedicines.
Tong F; Wang Y; Gao H
Curr Opin Biotechnol; 2024 Feb; 85():103045. PubMed ID: 38096768
[TBL] [Abstract][Full Text] [Related]
18. PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up.
Operti MC; Bernhardt A; Grimm S; Engel A; Figdor CG; Tagit O
Int J Pharm; 2021 Aug; 605():120807. PubMed ID: 34144133
[TBL] [Abstract][Full Text] [Related]
19. Development of Taiwan's strategies for regulating nanotechnology-based pharmaceuticals harmonized with international considerations.
Guo JW; Lee YH; Huang HW; Tzou MC; Wang YJ; Tsai JC
Int J Nanomedicine; 2014; 9():4773-83. PubMed ID: 25342901
[TBL] [Abstract][Full Text] [Related]
20. Exploiting endocytosis for nanomedicines.
Akinc A; Battaglia G
Cold Spring Harb Perspect Biol; 2013 Nov; 5(11):a016980. PubMed ID: 24186069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
